{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:53:45Z","timestamp":1795114425833,"version":"4.10.3"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2022-A-023"],"award-info":[{"award-number":["CSH-2022-A-023"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.diabres.2025.112357","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:25:22Z","timestamp":1751423122000},"page":"112357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes"],"prefix":"10.1016","volume":"226","author":[{"given":"Fu-Shun","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7183-2363","authenticated-orcid":false,"given":"Chen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-9627","authenticated-orcid":false,"given":"Chii-Min","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.112357_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMra022161","article-title":"Polycystic kidney disease","volume":"350","author":"Wilson","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.diabres.2025.112357_b0010","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112357_b0015","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Diseases E-EWGfIK. Autosomal dominant polycystic kidney disease: the changing face of clinical management","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112357_b0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneph.2016.135","article-title":"The importance of total kidney volume in evaluating progression of polycystic kidney disease","volume":"12","author":"Grantham","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.diabres.2025.112357_b0025","first-page":"86","article-title":"Autosomal dominant polycystic kidney disease and transplantation","volume":"14","author":"Niemczyk","year":"2009","journal-title":"Ann Transpl"},{"key":"10.1016\/j.diabres.2025.112357_b0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.13291019","article-title":"Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential","volume":"15","author":"Nowak","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2025.112357_b0035","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/ndt\/gfr744","article-title":"The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease","volume":"27","author":"Reed","year":"2012","journal-title":"Nephrol Dialy Transpl"},{"key":"10.1016\/j.diabres.2025.112357_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.diabres.2025.112357_b0045","unstructured":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788-1801."},{"key":"10.1016\/j.diabres.2025.112357_b0050","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/ckj\/sfad082","article-title":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","volume":"16","author":"Fernandez-Fernandez","year":"2023","journal-title":"Clin Kidney J"},{"issue":"1007\u20131023","key":"10.1016\/j.diabres.2025.112357_b0055","first-page":"e1005","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabres.2025.112357_b0060","doi-asserted-by":"crossref","first-page":"e2886","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes\/Metab Res Rev"},{"key":"10.1016\/j.diabres.2025.112357_b0065","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney International"},{"key":"10.1016\/j.diabres.2025.112357_b0070","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.3390\/jcm12196341","article-title":"Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease-a retrospective single-arm case series study","volume":"12","author":"Morioka","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2025.112357_b0075","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.diabres.2025.112357_b0080","first-page":"1244","article-title":"A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data","volume":"4","author":"Kahn","year":"2016","journal-title":"EGEMS (Wash DC)"},{"key":"10.1016\/j.diabres.2025.112357_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101783","article-title":"Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study","volume":"56","author":"Chang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabres.2025.112357_b0090","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.diabres.2025.112357_b0095","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.diabres.2025.112357_b0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.diabres.2025.112357_b0105","doi-asserted-by":"crossref","DOI":"10.1177\/2054358116679130","article-title":"Positive predictive values of international classification of diseases, 10th revision coding algorithms to identify patients with autosomal dominant polycystic kidney disease","volume":"3","author":"Kalatharan","year":"2016","journal-title":"Can J Kidney Health Disease"},{"key":"10.1016\/j.diabres.2025.112357_b0110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.ajkd.2010.05.013","article-title":"Validation of CKD and related conditions in existing data sets: a systematic review","volume":"57","author":"Grams","year":"2011","journal-title":"Am J Kidney Diseas"},{"key":"10.1016\/j.diabres.2025.112357_b0115","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejheart.2008.01.014","article-title":"Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure","volume":"10","author":"Ezekowitz","year":"2008","journal-title":"Euro J Heart Fail"},{"key":"10.1016\/j.diabres.2025.112357_b0120","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.diabres.2025.112357_b0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Disease Primers"},{"key":"10.1016\/j.diabres.2025.112357_b0130","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.34067\/KID.0007422020","article-title":"Examining the role of novel CKD therapies for the ADPKD patient","volume":"2","author":"Patel","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.diabres.2025.112357_b0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2025.112357_b0140","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in han: SPRD rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.diabres.2025.112357_b0145","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One1"},{"key":"10.1016\/j.diabres.2025.112357_b0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-088317","article-title":"Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial","volume":"14","author":"Bahlmann-Kroll","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabres.2025.112357_b0155","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13063-019-3474-5","article-title":"Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)","volume":"20","author":"Jensen","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.diabres.2025.112357_b0160","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"KWetal.Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"NealB","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.diabres.2025.112357_b0165","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112357_b0170","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.3390\/nu14173613","article-title":"The evolution of ketosis: potential impact on clinical conditions","volume":"14","author":"Dilliraj","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.diabres.2025.112357_b0175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.freeradbiomed.2023.08.013","article-title":"Dapagliflozin protects against doxorubicin-induced nephrotoxicity associated with nitric oxide pathway-a translational study","volume":"208","author":"Chang","year":"2023","journal-title":"Free Rad Biol Med"},{"key":"10.1016\/j.diabres.2025.112357_b0180","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ckj\/sfac029","article-title":"Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction","volume":"15","author":"Afsar","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.diabres.2025.112357_b0185","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.diabres.2025.112357_b0190","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1681\/ASN.V5122048","article-title":"Causes of death in autosomal dominant polycystic kidney disease","volume":"5","author":"Fick","year":"1995","journal-title":"J Am Soc Nephrol: JASN"},{"key":"10.1016\/j.diabres.2025.112357_b0195","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12882-021-02313-1","article-title":"Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease","volume":"22","author":"Gorriz","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.diabres.2025.112357_b0200","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.ajkd.2011.01.023","article-title":"Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study","volume":"57","author":"Patch","year":"2011","journal-title":"Am J Kidney Diseas"},{"key":"10.1016\/j.diabres.2025.112357_b0205","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2025.112357_b0210","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","article-title":"Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels","volume":"183","author":"D'Andrea","year":"2023","journal-title":"JAMA Int Med"},{"key":"10.1016\/j.diabres.2025.112357_b0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0453","article-title":"Sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and the incidence of acute kidney injury in Taiwan","volume":"6","author":"Chung","year":"2023","journal-title":"JAMA Network Open"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725003717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725003717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:04:17Z","timestamp":1753909457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725003717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":43,"alternative-id":["S0168822725003717"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112357","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112357"}}